Predictive Biomarkers in Prostate Cancer: Is It Time To Go “All In” on Liquid Biopsies?
An editorial to introduce an upcoming study that leverages Predicine’s next-gen liquid biopsy technology to investigate plasma cfDNA- and cfRNA-based AR molecular profiling in metastatic castration-resistant prostate cancer.
Clinical and genomic insights into circulating tumor DNA–based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer
Using Predicine’s cfDNA assay to analyze the molecular evolution over the mutational landscape from metastatic hormone-sensitive to castrate-resistant prostate cancer. Blood cfDNA-based gene deletion and amplification (BRCA, PTEN, RB, AR) are reported.
Next generation sequencing-based gene variant-oriented characterization in metastatic breast cancer: An innovative analysis using ctDNA
Lorenzo Gerratana, Qiang Zhang, Ami N Shah, Alessandra Franzoni, Jianjun Yu, Shidong Jia, Andrew A Davis, Youbin Zhang, Firas Wehbe, Amir Behdad, Leonidas C Platanias, William J Gradishar and Massimo Cristofanilli
Plasma cell free DNA (cfDNA) based somatic aberrations detected in treatment naïve metastatic hormone sensitive prostate cancer (mHSPC), hormonally ablated mHSPC and metastatic castration resistant prostate cancer (mCRPC) states and their impact on survival
Manish Kohli, Winston Tan, Tiantian Zheng, Amy Wang, Calvin Wong, Meng-Yao Tan, Shidong Jia, Jianjun Yu; H. Lee